Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the first participants have been dosed in a Phase 1 healthy volunteer study of HIB210, an investigational monoclonal antibody targeting C5aR1.
SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the first participants have been dosed in a Phase 1 healthy volunteer study of HIB210, an investigational monoclonal antibody targeting C5aR1. HIB210 follows felzartamab as the company’s second clinical-stage program and advances the company’s strategy of targeting and modulating the cellular drivers of IMDs. C5aR1, a downstream receptor of C5a, is believed to be implicated in neutrophil activation and chemotaxis. “Targeting C5aR1 has the potential to transform the treatment paradigm in several high burden IMDs,” said Travis Murdoch, M.D., Chief Executive Officer at HI-Bio. “C5aR1 is a validated target for several IMDs. Our preclinical characterization of HIB210 highlights its potential as a highly potent therapy. We look forward to evaluating HIB210 for patients with IMDs.” The Phase 1 healthy volunteer study is a double-blind, placebo-controlled, multiple ascending dose clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HIB210 in healthy volunteers (NCT05928585). Pharmacodynamic biomarkers of target engagement will be evaluated to provide proof-of-mechanism data. “We are excited that dosing of HIB210 comes on the heels of positive Phase 2 data and orphan drug designation for felzartamab, HI-Bio’s investigational agent for the treatment of primary membranous nephropathy,” said Murdoch. “As our second clinical-stage program, today’s HIB210 milestone is an important step forward in our mission to transform clinical immunology away from one-size-treats-all therapies and towards approaches that address the specific cellular drivers of immune-mediated diseases.” About HIB210 In 2018, MorphoSys entered into an exclusive strategic collaboration and regional licensing agreement with I-Mab Biopharma to develop and commercialize HIB210 (TJ210) in South Korea and Greater China, which encompasses Mainland China, Hong Kong, Macau and Taiwan. HIB210 is an investigational drug that has not yet been approved by any regulatory authorities. About HI-Bio
SOURCE HI-Bio |